Evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic was unprecedented in terms of urgency and scope. Responsibility for the safety, integrity and scientific validity of U.S. trials fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board, who in turn report to an oversight group. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.
